Why Nucor’s Stock Dip Could Be a Golden Opportunity in Disguise
Nucor (NYSE: NUE) isn’t just another steelmaker churning out metal for skyscrapers and rebar. It’s a powerhouse that has weathered economic storms, steel cycles, and shifting energy costs, all while steadily raising its dividend for over the past half century.
Yet, despite that remarkable consistency, investors seems to be snoozing on Nucor right now so is it time to buy?
» Read more about: Why Nucor’s Stock Dip Could Be a Golden Opportunity in Disguise »
Read More
Jack’s Fintech Giant Just Quadrupled Profits
The stock market has a way of turning heroes into villains overnight, and Block is a perfect case study. Just a few years ago, it was one of the hottest names on Wall Street, riding high on the wave of digital adoption.
Fast forward to today, and the stock is trading nearly 80% below its all-time highs.
» Read more about: Jack’s Fintech Giant Just Quadrupled Profits »
Read More
4% Dividend + 12x Earnings = Blockbuster in the Making
Merck has long been a pillar of stability in the pharmaceutical world, thanks in large part to the staggering success of its cancer drug Keytruda. But behind that success lies a quietly growing concern of what happens when the patents expire?
In a move that could reshape its future, Merck just announced a $10 billion acquisition of Verona Pharma.
» Read more about: 4% Dividend + 12x Earnings = Blockbuster in the Making »
Read More
Could BigBear.ai Stock Really 3x?
BigBear.ai (NYSE: BBAI) has all the buzzwords that investors love these days AI, defense, government contracts but does that make it a great investment?
Some traders are hoping the stock will 3x but as any seasoned investor knows, hope isn’t a strategy. If you’re wondering what it would actually take to get there,
» Read more about: Could BigBear.ai Stock Really 3x? »
Read More
4% Dividend + 12x Earnings = Blockbuster in the Making
Merck has long been a pillar of stability in the pharmaceutical world, thanks in large part to the staggering success of its cancer drug Keytruda. But behind that success lies a quietly growing concern of what happens when the patents expire?
In a move that could reshape its future, Merck just announced a $10 billion acquisition of Verona Pharma.
» Read more about: 4% Dividend + 12x Earnings = Blockbuster in the Making »
Read MoreThe Burst
Forget Nvidia, This Under-the-Radar Chip Stock Might Have More Upside
Chances are, you’ve never walked into a store and bought something with the ASML logo on it but almost every smartphone, tablet, or electric vehicle in your life probably wouldn’t exist without ASML’s technology humming away in the background.
This Dutch powerhouse doesn’t make chips, it makes the machines that make the chips.
» Read more about: Forget Nvidia, This Under-the-Radar Chip Stock Might Have More Upside »
Read MoreThe Spotlight
Where Will Robinhood Stock By 2030?
Robinhood doesn’t need to become the next Apple to reward shareholders. It just needs to keep doing what it’s doing, only better, smarter, and at a larger scale. Fortunately, that seems to be exactly the path it’s on.
Let’s uncover why Robinhood might be one of the more under-appreciated fintech stories unfolding right now.
» Read more about: Where Will Robinhood Stock By 2030? »
Read MoreThe Daily
US Stock Market Today: S&P 500, Nasdaq Hit Fresh Record Highs After Upbeat Alphabet Earnings
Wall Street’s S&P 500 and Nasdaq Composite surged to a fresh all-time high on Thursday, following upbeat quarterly earnings reported by Google-parent Alphabet.
The S&P 500 rose 0.2% to 6,371.9, whereas the Nasdaq Composite climbed 0.42% to 21,107.83.
The Dow Jones Industrial Average, however, slipped 289.39 points, or about 0.64%,